<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>20551113</Do_id>
  <Journal>Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</Journal>
  <Doc_title>Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient.</Doc_title>
  <Doc_abstract>Tyrosine kinase inhibitors (TKIs) are targeted treatments for various cancers. Skin toxicities are one of the most common nonhematological side-effects of TKIs. We report an imatinib mesylate (IM) induced hyperpigmented acne rosacea (AR) and sunitinib-induced palmar hyperkeratosis in the case with gastrointestinal stromal tumor. AR was arisen due to the discontinuation of IM. To the best of our knowledge, this kind of cutaneous side-effect with IM has not been documented previously.</Doc_abstract>
  <Doc_ChemicalList>Angiogenesis Inhibitors;Antineoplastic Agents;Benzamides;Histamine Antagonists;Indoles;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Pyrroles;Imatinib Mesylate;Protein-Tyrosine Kinases;sunitinib</Doc_ChemicalList>
  <Doc_meshdescriptors>Angiogenesis Inhibitors;Antineoplastic Agents;Benzamides;Biopsy;Gastrointestinal Stromal Tumors;Histamine Antagonists;Humans;Hyperpigmentation;Imatinib Mesylate;Indoles;Intestinal Neoplasms;Keratoderma, Palmoplantar;Liver Neoplasms;Male;Middle Aged;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Pyrroles;Rosacea;Skin;Skin Pigmentation;Treatment Outcome</Doc_meshdescriptors>
  <Doc_meshqualifiers>adverse effects;adverse effects;drug therapy;enzymology;pathology;therapeutic use;chemically induced;pathology;adverse effects;drug therapy;enzymology;pathology;chemically induced;pathology;drug therapy;secondary;adverse effects;adverse effects;antagonists &amp; inhibitors;metabolism;adverse effects;adverse effects;chemically induced;drug therapy;pathology;drug effects;pathology;drug effects</Doc_meshqualifiers>
</Document>
